MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched Magnolia Neurosciences Corporation, a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson’s Therapeutics Discovery division, including the Institute for Applied...
By July 31, all U.S. Department of Housing and Urban Development (HUD) housing will be required to be smokefree, in accordance to rule put...
MD Anderson’s Colorectal Cancer Moon Shot™ is committed to the prevention and early detection of the third most common cancer diagnosed in...
Increasing the dosage of a prescription smoking cessation medication by 1 milligram a day – from 2 to 3 milligrams – more than doubled abstinence rates after three months in some patients, according to research from MD Anderson Cancer Center.
The findings, published in the Journal of Clinical Psychopharmacology, found that this relatively small increase in varenicline benefited patients taking who had managed to cut down on smoking...
Older patients with non-metastatic breast cancer who have been treated modern chemotherapy drugs have a greater risk of secondary acute myeloid...